Recursion Pharmaceuticals Inc. has announced updates on its clinical programs, including the ongoing Phase 1/2 DAHLIA study for REC-1245, a potential first-in-class RBM39 degrader. This study is currently enrolling patient populations characterized by replication stress and DNA repair vulnerabilities. Additionally, Recursion has identified platinum-resistant ovarian cancer as the first combination cohort for its CDK7 inhibitor, REC-617, utilizing multi-omic and real-world patient data alongside causal AI modeling. The company reported these developments and financial results for the second quarter of 2025, highlighting their strategic use of advanced models and platform capabilities to enhance both internal and partnered programs. Results from these studies have not yet been presented.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。